Zhang Qianyi, Wang Jiamian, Chen Zhiyang, Qin Hao, Zhang Qichen, Tian Bo, Li Xilei
Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China.
Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200120, People's Republic of China.
Biomed Mater. 2025 Jan 23;20(2). doi: 10.1088/1748-605X/ada85e.
Nanoparticles (NPs)have been explored as drugs carriers for treating tumors and central nervous system (CNS)diseases and for oral administration. However, they lack satisfactory clinical efficacy due to poor extravasation and infiltration through biological barriers to target tissues. Most clinical antitumor NPs have been designed based on enhanced permeability and retention effects which are insufficient and heterogeneous in human tumors. The tight junctions3TJs: tight junctionsof the blood-brain barrier4BBB: blood-brain barrierand the small intestinal epithelium severely impede NPs from being transported into the CNS and blood circulation, respectively. By contrast, transcytosis enables NPs to bypass these physiological barriers and enhances their infiltration into target tissues by active transport. Here, we systematically review the mechanisms and putative application of NP transcytosis for targeting tumor and CNS tissues, explore oral NP administration, and propose future research directions in the field of NP transcytosis.
纳米颗粒(NPs)已被探索用作治疗肿瘤和中枢神经系统(CNS)疾病以及口服给药的药物载体。然而,由于其通过生物屏障向靶组织的渗出和浸润性较差,它们缺乏令人满意的临床疗效。大多数临床抗肿瘤纳米颗粒是基于增强的渗透和滞留效应设计的,而这种效应在人类肿瘤中是不足且不均匀的。血脑屏障(BBB)和小肠上皮的紧密连接严重阻碍纳米颗粒分别进入中枢神经系统和血液循环。相比之下,转胞吞作用使纳米颗粒能够绕过这些生理屏障,并通过主动转运增强其向靶组织的浸润。在此,我们系统地综述了纳米颗粒转胞吞作用靶向肿瘤和中枢神经系统组织的机制及假定应用,探讨口服纳米颗粒给药,并提出纳米颗粒转胞吞作用领域未来的研究方向。